Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01	$0.01	$0.01 ▼ $0.02	$1.19M	-1.01	435,993 shs	39,482 shs
GLYC GlycoMimetics	$0.16 -6.6%	$16.53	$14.06 ▼ $63.00	$10.00M	1.62	64,529 shs	1.05 million shs
IMRA IMARA	$49.95 +3.9%	$17.12	$0.97 ▼ $6.32	$1.31B	1.09	138,364 shs	61,249 shs
PCSA Heatwurx	$0.19 +2.4%	$0.26	$0.15 ▼ $3.10	$2.24M	1.3	4.92 million shs	2.85 million shs
SYBX Synlogic	$1.20 -0.3%	$1.17	$0.90 ▼ $1.88	$14.03M	0.55	16,905 shs	18,827 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	+1.01%	+6.38%	+1.01%	+9.89%	+11.11%
GLYC GlycoMimetics	0.00%	0.00%	-99.23%	-99.16%	-99.42%
IMRA IMARA	+0.11%	-1.56%	+4.84%	+660.44%	+660.44%
PCSA Heatwurx	-5.75%	-28.25%	-36.74%	-39.68%	-90.23%
SYBX Synlogic	+2.12%	+0.84%	+1.09%	+3.88%	-15.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVFM Evofem Biosciences	0.8495 of 5 stars	0.0	3.0	0.0	4.8	0.0	0.0	0.0
GLYC GlycoMimetics	1.2044 of 5 stars	0.0	3.0	0.0	4.6	1.1	1.7	0.0
IMRA IMARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	3.6605 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	1.3
SYBX Synlogic	0.5352 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A
IMRA IMARA	0.00	N/A	N/A	N/A
PCSA Heatwurx	3.00	Buy	$2.00	936.27% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYBX, GLYC, PCSA, IMRA, and EVFM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
IMRA IMARA	N/A	N/A	$0.66 per share	75.24	$3.44 per share	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.46 per share	N/A
SYBX Synlogic	$10K	1,399.32	N/A	N/A	$1.09 per share	1.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVFM Evofem Biosciences	$52.98M	-$0.05	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)
IMRA IMARA	$1.49M	$0.05	999.19	∞	N/A	N/A	2.12%	2.00%	N/A
PCSA Heatwurx	-$11.85M	-$3.08	N/A	N/A	N/A	N/A	-319.56%	-232.40%	8/12/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	8/6/2025 (Estimated)

Latest SYBX, GLYC, PCSA, IMRA, and EVFM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A
5/8/2025	Q1 2025	PCSA Heatwurx	-$0.77	-$0.30	+$0.47	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
IMRA IMARA	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVFM Evofem Biosciences	N/A	0.11	0.09
GLYC GlycoMimetics	N/A	1.92	1.92
IMRA IMARA	N/A	48.98	48.98
PCSA Heatwurx	N/A	2.93	2.93
SYBX Synlogic	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVFM Evofem Biosciences	0.22%
GLYC GlycoMimetics	75.19%
IMRA IMARA	49.28%
PCSA Heatwurx	91.93%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
EVFM Evofem Biosciences	0.21%
GLYC GlycoMimetics	8.70%
IMRA IMARA	37.30%
PCSA Heatwurx	9.60%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
IMRA IMARA	41	26.23 million	16.45 million	Not Optionable
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable

SYBX, GLYC, PCSA, IMRA, and EVFM Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, GLYC, PCSA, IMRA, and EVFM Company Descriptions

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)

As of 11:39 AM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)

Closing price 06/13/2025

Extended Trading

$0.16 0.00 (0.00%)

As of 06/13/2025 07:49 PM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

IMARA NASDAQ:IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Heatwurx NASDAQ:PCSA

$0.19 +0.00 (+2.39%)

Closing price 03:57 PM Eastern

Extended Trading

$0.19 0.00 (0.00%)

As of 04:55 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Synlogic NASDAQ:SYBX

$1.20 0.00 (-0.33%)

Closing price 01:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.08%)

As of 04:34 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time